ClinicalTrials.gg
CompletedNCT02307162Updated Oct 28, 2015

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

A Phase 1 interventional study of RPL554 and Placebo in Inflammatory Disorder of the Respiratory Tract and Chronic Obstructive Pulmonary Disorder, sponsored by Verona Pharma plc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
7th of 15
112 · median 79
Started
2014
the only one that year
Phase 1
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 1, and was the 1st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety of single doses and multiple doses of a new formulation of RPL554 in healthy subjects and subjects with chronic obstructive pulmonary disorder.

Read the detailed description

This is a randomised, double blind, placebo controlled study of a new suspension formulation of RPL554 comprising a Single Ascending Dose (SAD) phase (Part A) in healthy subjects, a Multiple Ascending Dose (MAD) phase (Part B) in healthy subjects and a MAD phase (Part C) in stable chronic obstructive pulmonary disease (COPD) subjects. Each cohort should comprise 10 subjects in a 7 active: 3 placebo ratio

Subjects will be screened in the 14 days before the first dose of study drug and have an end of study visit 4 to 10 days after the last dose of study drug.

Part A. Single Ascending Dose Study in Healthy Male Subjects aged 18-50. Each subject will receive a single dose of study drug. The starting dose will be 1.5 mg with planned escalation as 2 fold multiples unless the safety data indicates the escalation should be at smaller intervals. If RPL554 is not well tolerated at a particular dose level, the dose may be reduced for the next cohort.The decision on whether or not to escalate to each new dose level, and the dose, will be based on a formal review by the Dose Review Group (DRG).

Part B. Multiple Ascending Dose Study in Healthy Male Subjects aged 18-50. The starting dose for Part B will be determined from the data in Part A of the study. Each subject will receive the following doses of study drug and will be confined to the study centre during dosing: three doses at intervals of 8 hours on Days 1 to 5, followed by a single morning dose on Day 6.

The DRG may determine on the basis of safety or PK data that the dosing interval for subsequent cohorts will be every 12 hours, rather than every 8 hours.

Part C. Multiple Ascending Dose in moderate, stable COPD Subjects aged 40-75 Subjects will have no known significant concurrent diseases, will not have had a recent exacerbation, and will be expected to be able to withhold regular bronchodilator therapy for the duration of the treatment phase of the study. Rescue medication with ipratropium will be allowed (and its use recorded) and subjects may continue inhaled corticosteroids at a stable dose.

The dosing schedule will be the same as for Part B

Dose Escalation Procedures The decision on whether or not to escalate to each new dose level and from one part of the study to the next and the selected dose will be based on a formal review by the DRG of safety data.

The DRG will include the Principal Investigator and Sponsor's Medical Expert (and/or delegates) and will meet by teleconference to review safety data for each cohort. The DRG will review all available safety data (including adverse events [AEs], safety laboratory tests, spirometry and ECG data) collected up to 24 hours post dose for Part A, and for up to 24 hours post final dose for Parts B and C.

Data collected during the study will be entered on case report forms and transferred to a database using double entry. Blinding will be maintained until all queries are resolved and the database is locked. AEs will be summarised by study treatment and further by intensity and relationship to study treatment. The study will primarily be evaluated using descriptive statistics.

The sample size selected is not based on any formal power calculation.

03

Conditions studied

  • Inflammatory Disorder of the Respiratory Tract
  • Chronic Obstructive Pulmonary Disorder

Keywords

  • COPD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males following requirements, and agree not to donate sperm during study
  • 12-lead within normal range and no abnormality
  • Screening Holter report (minimum 18 hours) recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of subject safety or which may significantly impair interpretation
  • Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.
  • Body weight ≥50 kg.
  • Negative for , and
  • Negative cotinine tests prior to randomisation.

Additional Inclusion Criteria - Healthy Subjects (Parts A and B) only:

  • Males aged 18 and 50 years
  • Considered to be healthy
  • Vital sign assessments within ranges:

    • Systolic blood pressure 90 to 140 mmHg
    • Diastolic blood pressure 50 to 90 mmHg
    • Heart rate 45 to 90 bpm
  • 18 and 33 kg/m2 .
  • Spirometry readings ( and FVC) ≥80% of predicted normal.
  • Never smoked or is ex-smoker for ≥12 months with a smoking history of \<5 pack years

Additional Inclusion Criteria - Subjects (Part C) only:

  • Male and females aged 40 to 75 years
  • If female must be of non- ( or permanently sterilised)
  • BMI 18 and 33 kg/m2 (inclusive).
  • COPD diagnosis (defined by ATS/ERS guidelines Celli and MacNee, 2004) with symptoms compatible with COPD for at least 1 year
  • As defined in GOLD guidelines 2014: Post-bronchodilator spirometry at screening:

    • Post-salbutamol FEV1/FVC ratio 0.70
    • Post-salbutamol FEV1 ≥50 % and ≤80% of predicted normal
  • No current conditions that may significantly impair subject compliance, safety or influence study results.
  • Vital sign assessments within ranges:

    • Systolic blood pressure 100 to 160 mmHg
    • Diastolic blood pressure 50 to 90 mmHg
    • Heart rate 45 to 90 bpm
  • Clinically stable COPD in the last 4 weeks
  • Chest X-ray (post anterior) at screening, or within 6 months prior to screening showing no abnormalities, which are both clinically significant and unrelated to COPD.
  • Meet the concomitant medication restrictions
  • An ex-smoker for ≥6 months with a smoking history of ≥10 pack years
  • Capable of withdrawing from regular bronchodilators

Exclusion criteria

Exclusion Criteria:

  • Respiratory tract infection (both upper and lower) treated with antibiotics in last 12 weeks
  • abnormal values for safety laboratory tests or physical examination
  • History or suspected history of drug or alcohol abuse within the past 5 years.
  • Known allergy to the study drug or any of the of the formulation.
  • Donated blood or blood products or had substantial loss of blood (more than 500 mL) in last 4 weeks or intention to donate blood or blood products during the study.
  • Received an experimental drug or used an experimental medical device within 3 months or within a period less than 5 times the drug's half-life, whichever is longer
  • Pre-planned surgery or procedures that would interfere with the conduct of the study.
  • Employee of the Investigator or study site or family members of the employees or the Investigator.
  • History of regular alcohol consumption within last 6 months
  • Unable or unwilling to comply fully with the study protocol.
  • Mentally or legally incapacitated.
  • Unable or unwilling to undergo multiple venepuncture procedures or having poor access to veins suitable for cannulation.
  • History of of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.

Additional Exclusion Criteria - Healthy Subjects (Parts A and B) only

-Positive test for alcohol or drugs of abuse

Additional Exclusion Criteria - Subjects (Part C) only

  • Positive test for alcohol or drugs of abuse prior to randomisation (unless explained by the subject's medication).
  • A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
  • COPD exacerbation requiring oral within the last 12 months
  • A history of one or more hospitalization for COPD in last 12 months
  • Evidence of cor pulmonale or clinically significant pulmonary hypertension.
  • Other respiratory disorders: Subjects with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnoea, known alpha1-AT deficiency or other active pulmonary diseases.
  • Previous lung resection or lung reduction surgery.
  • Active participation in a pulmonary rehabilitation program.
  • History of chronic uncontrolled disease that the Investigator believes are clinically significant.
  • Documented severe cardiovascular disease: angina, recent or suspected myocardial infarction, History of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
  • Major surgery, (requiring general anaesthesia) within last 6 weeks before the screening visit, or will not have fully recovered from surgery, or planned surgery through the end of the study.
  • History of significant non compliance in previous studies or with prescribed medications.
  • Requires oxygen, even on an occasional basis.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Placebo comparator
    Dummy solution

    Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)

    Drug: Placebo

  • Experimental
    RPL554 suspension

    Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C). Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B

    Drug: RPL554

Interventions

  • DrugRPL554

    Phosphodiesterase 3 and 4 Inhibitor

  • DrugPlacebo

    Dummy solution

06

What researchers measure

Primary outcomes

  1. Adverse events

    Adverse events

    Time frame: From screening until last visit (up to 10 days after last dose)

  2. Vital signs

    Blood pressure and pulse rate

    Time frame: Pre-dose, up to 24 hours post last dose and last visit

  3. Laboratory safety assessments

    Biochemistry, haematology and urinalysis

    Time frame: Pre-dose, up to 24 hours post last dose and last visit

  4. ECG

    ECG

    Time frame: Pre-dose, up to 24 hours post last dose and last visit

  5. Physical Examination

    Time frame: Pre-dose, 24 hours post last dose and last visit

  6. Holter Monitoring

    Continuous heart monitoring

    Time frame: 24 hours post dose

Secondary outcomes

  1. Pharmacokinetics (trough measurement Blood sampling for RPL554 concentration)

    Blood sampling for RPL554 concentration

    Time frame: 24 hour profile after first and last dose, trough measurement on Days 2-5 for Parts B and C

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, M23 9QP, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2014
First posted
Dec 4, 2014
Start
Dec 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02307162
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Dec 2014
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Oct 28, 2015

Study contacts

Dave Singh
principal investigator · Medicines Evaluation Unit, Manchester

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion